FDA Warns Against Ovarian Cancer Screening

With five-year cancer survival at an all-time high, does this mean people are living longer?

“It's really, really important that every year since 1991, cancer mortality has dropped by a little bit, and it did again!” said Paul Goldberg, editor and publisher of The Cancer Letter. “Now, mortality is a good metric, age-adjusted mortality. As far as survival, well, that's not so good.”

January 21, 2026

Clinical Health Equity

New Medicaid work requirements could lead to 1.6 million missed cancer screenings over two years

New Medicaid work requirements included in President Donald Trump’s “One Big Beautiful Bill Act” could result in as many as 1.6 million missed screenings for breast, colon, and lung cancers within the first two years, researchers at the University of Chicago reported in a paper published in JAMA Oncology earlier this month.

Blood test may help identify which colon cancer patients benefit from NSAIDs

A blood test could help doctors decide which patients with colon cancer should receive anti-inflammatory medication along with chemotherapy after surgery.

January 09, 2026

Vol.52 No.1

Guest Editorial

Mail-out colorectal cancer screening programs extend, rather than replace, clinical care

As a gastroenterologist, I’ve had the sobering experience of delivering a colorectal cancer diagnosis for far too many patients and family members. Some meant to get screened but never found the time. Others thought it didn’t apply to them or assumed it would be too inconvenient.

ChristianaCare research reveals drivers behind advanced breast cancer in hotspots

Reduced screening rates and a higher prevalence of triple-negative breast cancer are driving elevated rates of advanced breast cancer in a geographic hotspot in Wilmington, Delaware, according to findings by researchers at ChristianaCare’s Cawley Center for Translational Cancer Research at the Helen F. Graham Cancer Center & Research Institute.

July 25, 2025

Vol.51 No.29

Drugs & Targets

Cardiac CT scanner receives FDA clearance

Arineta, a provider of cardiovascular imaging solutions, announced that its SpotLight Duo cardiac CT scanner has received 510(k) clearance from FDA for low-dose lung cancer screening. This clearance allows providers to use a single ultra-fast CT platform for both cardiac and lung imaging and diagnostics, delivering more complete care to high-risk patients.

May 23, 2025

Vol.51 No.20

FDA Warns Against Ovarian Cancer Screening

YOU MAY BE INTERESTED IN

With five-year cancer survival at an all-time high, does this mean people are living longer?

New Medicaid work requirements could lead to 1.6 million missed cancer screenings over two years

Blood test may help identify which colon cancer patients benefit from NSAIDs

Mail-out colorectal cancer screening programs extend, rather than replace, clinical care

ChristianaCare research reveals drivers behind advanced breast cancer in hotspots

Cardiac CT scanner receives FDA clearance

Renew today!

Subscriber content

Never miss an issue!

Login